@prefix prodottidellaricerca: . @prefix istituto: . @prefix prodotto: . istituto:CDS040 prodottidellaricerca:prodotto prodotto:ID63092 . @prefix pubblicazioni: . @prefix unitaDiPersonaleEsterno: . unitaDiPersonaleEsterno:ID8266 pubblicazioni:autoreCNRDi prodotto:ID63092 . @prefix modulo: . modulo:ID5927 prodottidellaricerca:prodotto prodotto:ID63092 . modulo:ID5952 prodottidellaricerca:prodotto prodotto:ID63092 . @prefix rdf: . @prefix retescientifica: . prodotto:ID63092 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID63092 rdfs:label "Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID63092 pubblicazioni:anno "2011-01-01T00:00:00+01:00"^^xsd:gYear . @prefix skos: . prodotto:ID63092 skos:altLabel "
Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. (2011)
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy
"^^rdf:HTML ; pubblicazioni:autori "Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA."^^xsd:string ; pubblicazioni:paginaInizio "538"^^xsd:string ; pubblicazioni:paginaFine "550"^^xsd:string ; pubblicazioni:numeroVolume "2"^^xsd:string ; pubblicazioni:affiliazioni "Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858 USA; Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell\u0092Apparato Locomotore, Universit\u00E0 di Bologna, Bologna, Italy; IGM-CNR, Sezione di Bologna, c/o IOR, Bologna, Italy; Department of Biomedical Sciences, University of Catania, Catania, Italy; Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine"^^xsd:string ; pubblicazioni:titolo "Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy"^^xsd:string ; prodottidellaricerca:abstract "Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs is clearly important as these are frequently used therapeutic approaches. A signaling pathway often involved in chemo- and hormonal-resistance is the Ras/PI3K/PTEN/Akt/mTOR cascades. In the studies presented in this report, we have examined the effects of constitutive activation of Akt on the sensitivity of MCF-7 breast cancer cells to chemotherapeutic- and hormonal-based drugs as well as mTOR inhibitors. MCF-7 cells which expressed a constitutively-activated Akt-1 gene [deltaAkt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking deltaAkt-1(CA). Cells which expressed deltaAkt-1 (CA) were hypersensitive to the mTOR inhibitor rapamycin. Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed deltaAkt-1 (CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Understanding how breast cancers respond to chemo- and hormonal-based therapies and the mechanisms by which they can become drug resistant may enhance our ability to treat breast cancer. These results also document the potential importance of knowledge of the mutations present in certain cancers which may permit more effective therapies." ; prodottidellaricerca:prodottoDi modulo:ID5927 , istituto:CDS040 , modulo:ID5952 ; pubblicazioni:autoreCNR unitaDiPersonaleEsterno:ID8266 . @prefix parolechiave: . prodotto:ID63092 parolechiave:insiemeDiParoleChiave . parolechiave:insiemeDiParoleChiaveDi prodotto:ID63092 .